Preparation and Anticancer Effect of Flufenamic Acid-loaded Chitosan Nanoparticle

Flufenamic acid (FA) is well known as a bladder cancer treatment drug, but when used by itself, its therapeutic effect is halved due to the immune response and drug resistance in the body. To solve this problem, in this study, nanoparticles with a core-shell structure were prepared and FA was encapsulated at the hydrophobic core to maximize the therapeutic effect. LMWSC-g-LA (LMLA) was synthesized by chemical modification of the hydrophobic substance lauric acid (LA) in the hydrophilic polymer low molecular weight water-soluble chitosan (LMWSC), and it was confirmed that the synthesis was successful through H-1 NMR analysis. In addition, FA-encapsulated LMLA (LMLAF) nanoparticles were prepared by dialysis method, and utilization of LMLA as FA drug delivery carrier has proven by various physicochemical properties analysis using DLS, UV-vis spectrophotometer, fluorophotometer, and TEM. Moreover, results of the cytotoxicity and anticancer effects of LMLA and LMLAF using MTT assay in various cells showed non-toxic and high anticancer effects. These results suggest that LMLAF nanoparticles can be used as an anticancer agent because they can maximize bladder cancer treatment efficiency while being safe in the body.